Phase 1 N=36 First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Advanced Solid Tumors
Primary: Maximum Tolerated Dose (MTD) — 5 mg BID
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 79360.0; 77180.0; 20550.0; 18800.0 ng*hr/mL
Phase 1 N=28 Telmisartan and Amlodipine Versus Monocomponent Tablets
Hypertension
Primary: Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72) — 260.7971; 276.6315 nanograms*hour/milliliter — p=0.005
Phase 1 N=19 Melatonin Osteoporosis Prevention Study
Osteoporosis · Osteopenia
Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL
Phase 1 N=20 PPI and Clopidogrel Response
Drug Interaction
Primary: Platelet Function as Assessed by the P2Y12 Reactivity Index — 56.1; 61.6; 56; 61 Percentage of platelet reactivity index
Phase 1 N=44 Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
Dry Eye Syndromes
Primary: Concentration of Cyclosporine Measured in Blood at Day 1 in the Parallel-Group Phase (PGP) — NA; NA; NA; NA Nanogram/milliliter (ng/mL)
Phase 1 N=24 Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
Transplant Rejection · Renal Transplantation
Primary: Maximum Observed Blood Concentration at Steady State (Cmax,ss) — 14.07 nanogram per milliliter (ng/mL)
Phase 1 N=96 Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers
Healthy
Primary: Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing…
Phase 1 N=172 Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Cancer
Primary: Maximum Tolerated Dose (MTD) — NA; NA; 590; 590 mg
Phase 1 N=46 Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors
Cancer
Primary: Maximum Tolerated Dose (MTD) — 610 mg
Phase 1 N=1,115 Cognitive Health Promotion Project in the Community
Alteration of Cognitive Function · Dietary Modification
Primary: Change of Cognitive Function Measured by a Mini Mental State Examination Scores on a Scale According to Study Group — 23.3; 23.8; 23.1; 23.7 units on a scale
Phase 1 N=31 A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
Breast Cancer · Non-small Cell Lung Cancer · Non-Hodgkins Lymphoma
Primary: Time to Reach Maximum Observed Plasma Concentration (Tmax) — 0.35; 0.34 hours
Phase 1 N=31 Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)
Hypercholesterolemia, Dyslipidemia
Primary: Arachidonic Acid Level After 2 Weeks of Treatment — 259.1; 269.6 nmol — p=0.455
Phase 1 N=26 An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
Anemia, Sickle Cell
Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] for Prasugrel's…
Phase 1 N=3 Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of Lipotecan — 50 mg/m^2